ArticleChemphyschem : a European journal of chemical physics and physical chemistry2025
Targeted Delivery of Lidocaine in Breast Cancer Cells via Zeolitic Imidazolate Framework-8 Nanoparticles.
Article in Chemphyschem : a European journal of chemical physics and physical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The effect of lidocaine in breast cancer: a concise overview of preclinical and clinical evidence.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The aim of this article is to use zeolitic imidazolate framework-8 (ZIF-8) metal-organic frameworks (MOFs) as drug delivery system for lidocaine, a local anesthetic with recently discovered antitumoral effects, in particular for the early-stage treatment of breast cancer. A previously optimized ZIF-8 synthetic method is employed, and the prepared material is deeply characterized with X-ray powder diffraction (XRPD), surface area analysis, scanning electron microscopy (SEM), and thermogravimetric analysis (TGA). After confirming the successful synthetic outcomes, a tailored loading procedure is developed to incorporate lidocaine within the ZIF-8 pores. The effectiveness of this loading process is verified using UV-Vis spectroscopy and TGA, while SEM and attenuated total reflectance-mid infrared spectroscopy further confirms the presence of lidocaine within the MOF pores. Afterwards, the pH-responsive drug release by dialyzing the lidocaine@ZIF-8 sample is tested either at physiological or at weakly acid pH values by UV spectroscopy on the dialysis solutions. Finally, the MDA-MB-231 breast cancer cells viability of lidocaine@ZIF-8 system is tested and compared with the free drug and the MOF alone, confirming its significant capabilities in the reduction of cells viability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.